| First Author | Contreras JR | Year | 2015 |
| Journal | Oncotarget | Volume | 6 |
| Issue | 13 | Pages | 11023-37 |
| PubMed ID | 25906746 | Mgi Jnum | J:309315 |
| Mgi Id | MGI:6757305 | Doi | 10.18632/oncotarget.3433 |
| Citation | Contreras JR, et al. (2015) MicroRNA-146a modulates B-cell oncogenesis by regulating Egr1. Oncotarget 6(13):11023-37 |
| abstractText | miR-146a is a NF-kappaB induced microRNA that serves as a feedback regulator of this critical pathway. In mice, deficiency of miR-146a results in hematolymphoid cancer at advanced ages as a consequence of constitutive NF-kappaB activity. In this study, we queried whether the deficiency of miR-146a contributes to B-cell oncogenesis. Combining miR-146a deficiency with transgenic expression of c-Myc led to the development of highly aggressive B-cell malignancies. Mice transgenic for c-Myc and deficient for miR-146a were characterized by significantly shortened survival, increased lymph node involvement, differential involvement of the spleen and a mature B-cell phenotype. High-throughput sequencing of the tumors revealed significant dysregulation of approximately 250 genes. Amongst these, the transcription factor Egr1 was consistently upregulated in mice deficient for miR-146a. Interestingly, transcriptional targets of Egr1 were enriched in both the high-throughput dataset and in a larger set of miR-146a-deficient tumors. miR-146a overexpression led to downregulation of Egr1 and downstream targets with concomitant decrease in cell growth. Direct targeting of the human EGR1 by miR-146a was seen by luciferase assay. Together our findings illuminate a bona fide role for miR-146a in the modulation of B-cell oncogenesis and reveal the importance of understanding microRNA function in a cell- and disease-specific context. |
